MA43717A - Anticorps anti-tnf et fragments fonctionnels de ceux-ci - Google Patents
Anticorps anti-tnf et fragments fonctionnels de ceux-ciInfo
- Publication number
- MA43717A MA43717A MA043717A MA43717A MA43717A MA 43717 A MA43717 A MA 43717A MA 043717 A MA043717 A MA 043717A MA 43717 A MA43717 A MA 43717A MA 43717 A MA43717 A MA 43717A
- Authority
- MA
- Morocco
- Prior art keywords
- functional fragments
- tnf antibodies
- tnf
- antibodies
- fragments
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16160907.8A EP3219726B1 (fr) | 2016-03-17 | 2016-03-17 | Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci |
| PCT/EP2017/056237 WO2017158092A1 (fr) | 2016-03-17 | 2017-03-16 | Anticorps anti-tnfα et fragments fonctionnels de ceux-ci |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA43717A true MA43717A (fr) | 2018-11-28 |
| MA43717B1 MA43717B1 (fr) | 2023-11-30 |
Family
ID=55542576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA43717A MA43717B1 (fr) | 2016-03-17 | 2017-03-16 | Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci |
Country Status (39)
| Country | Link |
|---|---|
| US (3) | US11459383B2 (fr) |
| EP (3) | EP3219726B1 (fr) |
| JP (2) | JP7129398B2 (fr) |
| KR (2) | KR20220158877A (fr) |
| CN (1) | CN109071650B (fr) |
| AR (1) | AR107917A1 (fr) |
| AU (1) | AU2017235387B2 (fr) |
| BR (1) | BR112018016667A2 (fr) |
| CA (1) | CA3011784C (fr) |
| CL (1) | CL2018002649A1 (fr) |
| CO (1) | CO2018009783A2 (fr) |
| CR (1) | CR20180448A (fr) |
| CY (1) | CY1123784T1 (fr) |
| DK (2) | DK3219726T3 (fr) |
| EA (1) | EA039760B1 (fr) |
| ES (2) | ES2836349T3 (fr) |
| FI (1) | FI3430043T3 (fr) |
| GE (1) | GEP20217307B (fr) |
| HR (2) | HRP20231464T1 (fr) |
| HU (2) | HUE052773T2 (fr) |
| IL (1) | IL261031A (fr) |
| JO (2) | JOP20170064B1 (fr) |
| LT (2) | LT3219726T (fr) |
| MA (1) | MA43717B1 (fr) |
| MD (1) | MD3430043T2 (fr) |
| MX (1) | MX2018011258A (fr) |
| MY (1) | MY194041A (fr) |
| PH (1) | PH12018501907A1 (fr) |
| PL (2) | PL3219726T3 (fr) |
| PT (2) | PT3219726T (fr) |
| RS (2) | RS61374B1 (fr) |
| SA (1) | SA518400027B1 (fr) |
| SG (1) | SG11201807062RA (fr) |
| SI (2) | SI3219726T1 (fr) |
| TN (1) | TN2018000298A1 (fr) |
| TW (2) | TWI784945B (fr) |
| UY (1) | UY37157A (fr) |
| WO (1) | WO2017158092A1 (fr) |
| ZA (4) | ZA202108599B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS61412B1 (sr) | 2016-03-17 | 2021-03-31 | Tillotts Pharma Ag | Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti |
| DK3219726T3 (da) * | 2016-03-17 | 2020-12-07 | Tillotts Pharma Ag | Anti-TNF-alfa-antistoffer og funktionelle fragmenter deraf |
| US10759852B2 (en) | 2016-03-17 | 2020-09-01 | Numab Innovation Ag | Anti-TNF-alpha-antibodies and functional fragments thereof |
| US10787508B2 (en) | 2016-03-17 | 2020-09-29 | Numab Innovation Ag | Anti-TNFα-antibodies and functional fragments thereof |
| LT3456736T (lt) * | 2017-09-19 | 2021-06-10 | Tillotts Pharma Ag | Antikūnų variantai |
| EP3456737B1 (fr) * | 2017-09-19 | 2024-02-14 | Tillotts Pharma Ag | Variantes d'anticorps |
| EP3456738A1 (fr) * | 2017-09-19 | 2019-03-20 | Tillotts Pharma Ag | Variantes d'anticorps |
| WO2020114616A1 (fr) | 2018-12-07 | 2020-06-11 | Tillotts Pharma Ag | Traitement topique d'une diarrhée, d'une colite ou d'une entérocolite induite par un inhibiteur de point de contrôle immunitaire au moyen d'anticorps et de fragments de ceux-ci |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| WO1992003918A1 (fr) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Animaux non humains transgeniques capables de produire des anticorps heterologues |
| GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
| US5919452A (en) | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
| EP0519596B1 (fr) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | Procédé pour réduire l'immunogénicité des domaines variables d'anticorps |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| ATE275198T1 (de) | 1991-12-02 | 2004-09-15 | Medical Res Council | Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| NO309690B1 (no) | 1995-01-23 | 2001-03-12 | Western Atlas Int Inc | Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn |
| EP1978033A3 (fr) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Anticorps humains dérivés à partir de xénosouris immunisée |
| CA2219486A1 (fr) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Anticorps humains derives de xeno-souris immunisees |
| DK0929578T3 (da) * | 1996-02-09 | 2003-08-25 | Abbott Lab Bermuda Ltd | Humane antistoffer, der binder human TNFalfa |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| CA2616914C (fr) | 1996-12-03 | 2012-05-29 | Abgenix, Inc. | Anticorps de liaison de recepteur d'egf |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| CZ294425B6 (cs) | 1997-04-14 | 2005-01-12 | Micromet Ag | Způsob výroby anti-humánního antigenového receptoru, anti-humánní antigenový receptor, řetězec VH a VL, souprava pro selekci anti-humánních antigenových receptorů a farmaceutická kompozice, obsahující uvedený receptor |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| PT1135498E (pt) | 1998-11-18 | 2008-04-30 | Genentech Inc | Variantes de anticorpos com maior afinidade de ligação em comparação com os anticorpos parentais |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| US7431927B2 (en) | 2005-03-24 | 2008-10-07 | Epitomics, Inc. | TNFα-neutralizing antibodies |
| CN102924597A (zh) | 2005-06-07 | 2013-02-13 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | 抑制TNFα的稳定和可溶的抗体 |
| KR102007492B1 (ko) | 2008-06-25 | 2019-08-05 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화 |
| HUE039692T2 (hu) | 2008-06-25 | 2019-01-28 | Esbatech Alcon Biomed Res Unit | TNF-et gátló stabil és oldható ellenanyagok |
| KR20110031373A (ko) | 2008-07-10 | 2011-03-25 | 에스바테크, 언 알콘 바이오메디칼 리서치 유닛 엘엘씨 | 마크로분자 전달을 증강하는 방법 및 조성물 |
| RU2012147249A (ru) * | 2010-04-07 | 2014-05-20 | Эббви Инк. | TNF-α- СВЯЗЫВАЮЩИЕ БЕЛКИ |
| EP2593476A2 (fr) * | 2010-07-16 | 2013-05-22 | Ablynx N.V. | Molécules de liaison à un antigène à domaine unique modifiées et leurs utilisations |
| CN102443063B (zh) * | 2010-09-30 | 2013-10-23 | 成都康弘生物科技有限公司 | 抗TNFα的人源化Fab和人源化抗体及其用途 |
| AU2014301629B2 (en) | 2013-06-26 | 2020-02-06 | Numab Therapeutics AG | Novel antibody frameworks |
| EP3062818B1 (fr) * | 2013-11-01 | 2019-09-11 | IBC Pharmaceuticals, Inc. | Anticorps bispécifiques qui neutralisent à la fois tnf-alpha et il-6 : nouvel agent thérapeutique pour traiter une maladie auto-immune |
| RU2706551C2 (ru) * | 2014-03-26 | 2019-11-19 | Селл Медика Свитзерлэнд Аг | Связывающие элементы к фно-альфа |
| DK3219726T3 (da) * | 2016-03-17 | 2020-12-07 | Tillotts Pharma Ag | Anti-TNF-alfa-antistoffer og funktionelle fragmenter deraf |
| US10787508B2 (en) | 2016-03-17 | 2020-09-29 | Numab Innovation Ag | Anti-TNFα-antibodies and functional fragments thereof |
| US10759852B2 (en) | 2016-03-17 | 2020-09-01 | Numab Innovation Ag | Anti-TNF-alpha-antibodies and functional fragments thereof |
| RS61412B1 (sr) | 2016-03-17 | 2021-03-31 | Tillotts Pharma Ag | Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti |
-
2016
- 2016-03-17 DK DK16160907.8T patent/DK3219726T3/da active
- 2016-03-17 EP EP16160907.8A patent/EP3219726B1/fr active Active
- 2016-03-17 LT LTEP16160907.8T patent/LT3219726T/lt unknown
- 2016-03-17 PL PL16160907T patent/PL3219726T3/pl unknown
- 2016-03-17 RS RS20210112A patent/RS61374B1/sr unknown
- 2016-03-17 HU HUE16160907A patent/HUE052773T2/hu unknown
- 2016-03-17 ES ES16160907T patent/ES2836349T3/es active Active
- 2016-03-17 PT PT161609078T patent/PT3219726T/pt unknown
- 2016-03-17 SI SI201631040T patent/SI3219726T1/sl unknown
-
2017
- 2017-03-16 KR KR1020227040533A patent/KR20220158877A/ko not_active Application Discontinuation
- 2017-03-16 PL PL17710748.9T patent/PL3430043T3/pl unknown
- 2017-03-16 WO PCT/EP2017/056237 patent/WO2017158092A1/fr active Application Filing
- 2017-03-16 EP EP17710748.9A patent/EP3430043B1/fr active Active
- 2017-03-16 JO JOP/2017/0064A patent/JOP20170064B1/ar active
- 2017-03-16 HR HRP20231464TT patent/HRP20231464T1/hr unknown
- 2017-03-16 ES ES17710748T patent/ES2963221T3/es active Active
- 2017-03-16 CA CA3011784A patent/CA3011784C/fr active Active
- 2017-03-16 EP EP23192170.1A patent/EP4275745A3/fr active Pending
- 2017-03-16 HU HUE17710748A patent/HUE064238T2/hu unknown
- 2017-03-16 LT LTEPPCT/EP2017/056237T patent/LT3430043T/lt unknown
- 2017-03-16 MA MA43717A patent/MA43717B1/fr unknown
- 2017-03-16 PT PT177107489T patent/PT3430043T/pt unknown
- 2017-03-16 MY MYPI2018001566A patent/MY194041A/en unknown
- 2017-03-16 DK DK17710748.9T patent/DK3430043T3/da active
- 2017-03-16 GE GEAP201714876A patent/GEP20217307B/en unknown
- 2017-03-16 US US16/085,506 patent/US11459383B2/en active Active
- 2017-03-16 AU AU2017235387A patent/AU2017235387B2/en active Active
- 2017-03-16 CN CN201780015298.5A patent/CN109071650B/zh active Active
- 2017-03-16 JP JP2019500013A patent/JP7129398B2/ja active Active
- 2017-03-16 FI FIEP17710748.9T patent/FI3430043T3/fi active
- 2017-03-16 MD MDE20190099T patent/MD3430043T2/ro unknown
- 2017-03-16 EA EA201891788A patent/EA039760B1/ru unknown
- 2017-03-16 SG SG11201807062RA patent/SG11201807062RA/en unknown
- 2017-03-16 RS RS20231087A patent/RS64830B1/sr unknown
- 2017-03-16 SI SI201731446T patent/SI3430043T1/sl unknown
- 2017-03-16 TN TNP/2018/000298A patent/TN2018000298A1/en unknown
- 2017-03-16 MX MX2018011258A patent/MX2018011258A/es unknown
- 2017-03-16 BR BR112018016667A patent/BR112018016667A2/pt unknown
- 2017-03-16 CR CR20180448A patent/CR20180448A/es unknown
- 2017-03-16 KR KR1020187022632A patent/KR102470235B1/ko active IP Right Grant
- 2017-03-17 UY UY0001037157A patent/UY37157A/es not_active Application Discontinuation
- 2017-03-17 TW TW106108832A patent/TWI784945B/zh active
- 2017-03-17 AR ARP170100675A patent/AR107917A1/es unknown
- 2017-03-17 TW TW111145252A patent/TWI829444B/zh active
-
2018
- 2018-08-07 IL IL261031A patent/IL261031A/en unknown
- 2018-09-06 PH PH12018501907A patent/PH12018501907A1/en unknown
- 2018-09-14 CL CL2018002649A patent/CL2018002649A1/es unknown
- 2018-09-16 SA SA518400027A patent/SA518400027B1/ar unknown
- 2018-09-17 CO CONC2018/0009783A patent/CO2018009783A2/es unknown
-
2021
- 2021-01-13 CY CY20211100021T patent/CY1123784T1/el unknown
- 2021-01-22 HR HRP20210123TT patent/HRP20210123T1/hr unknown
- 2021-04-22 JO JOP/2021/0085A patent/JOP20210085A1/ar unknown
- 2021-11-04 ZA ZA2021/08599A patent/ZA202108599B/en unknown
- 2021-11-04 ZA ZA2021/08602A patent/ZA202108602B/en unknown
- 2021-11-04 ZA ZA2021/08601A patent/ZA202108601B/en unknown
- 2021-11-04 ZA ZA2021/08600A patent/ZA202108600B/en unknown
-
2022
- 2022-06-06 JP JP2022091271A patent/JP2022130407A/ja active Pending
- 2022-08-18 US US17/890,857 patent/US20230272059A1/en active Pending
- 2022-10-03 US US17/958,759 patent/US20230279091A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46525A (fr) | Anticorps anti-lag-3 et compositions | |
| IL265800A (en) | Anti-lag-3 antibodies and methods of using them | |
| IL272274A (en) | Antibodies 4H-7B methods for their use | |
| MA44659A (fr) | Anticorps anti-tim-3 et compositions | |
| KR102162129B9 (ko) | 항-갈렉틴-9 항체 및 이의 용도 | |
| KR20180084817A (ko) | 항-siglec-9 항체 및 이의 이용 방법 | |
| DK3618863T3 (da) | Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf | |
| MA55347A (fr) | Anticorps anti-lag3 et fragments de fixation à l'antigène | |
| SG10201912879YA (en) | Anti-sirp-alpha antibodies and methods of use thereof | |
| MA43717A (fr) | Anticorps anti-tnf et fragments fonctionnels de ceux-ci | |
| MA43576A (fr) | Anticorps anti-lag3 et fragments de fixation à l'antigène | |
| DK3601358T3 (da) | Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf | |
| SG10201912563XA (en) | Anti-tim-3 antibodies and methods of use thereof | |
| DK3653221T3 (da) | Anti-pvrig-antistoffer og anvendelsesfremgangsmåder | |
| MA42243A (fr) | Anticorps de facteur xi et méthodes d'utilisation | |
| EA201790984A1 (ru) | Анти-cd79b антитела и способы их применения | |
| MA49726A (fr) | Formulation d'anticorps anti-cgrp | |
| EA201691610A1 (ru) | Анти-jagged1 антитела и способы применения | |
| MA43738A (fr) | Anticorps anti-tnfalpha et leurs fragments fonctionnels | |
| ZA202003695B (en) | Anti-neuropilin antigen-binding proteins and methods of use thereof | |
| IL264528B1 (en) | fcrn antibodies and methods of using them | |
| IL267673A (en) | Broad neutralizing antibodies against hiv-1 and methods of using them | |
| IL275070A (en) | FCRN antibodies and methods of using them | |
| CR20180296A (es) | ANTICUERPOS ANTI-HtrA1 Y MÉTODOS DE USO | |
| IL265957A (en) | Anti-c1s antibodies and methods of using them |